332 related articles for article (PubMed ID: 10074534)
21. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
[TBL] [Abstract][Full Text] [Related]
22. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
23. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
[TBL] [Abstract][Full Text] [Related]
25. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
Preiksaitis JK; Diaz-Mitoma F; Mirzayans F; Roberts S; Tyrrell DL
J Infect Dis; 1992 Nov; 166(5):986-94. PubMed ID: 1328412
[TBL] [Abstract][Full Text] [Related]
26. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
27. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
29. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
30. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease.
Rosselet A; Vu DH; Meylan P; Chaubert AS; Schapira M; Pascual M; Aubert V; Tissot JD; Duchosal MA
Clin Transplant; 2009; 23(1):74-82. PubMed ID: 19200218
[TBL] [Abstract][Full Text] [Related]
31. The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
Preiksaitis J; Allen U; Bollard CM; Dharnidharka VR; Dulek DE; Green M; Martinez OM; Metes DM; Michaels MG; Smets F; Chinnock RE; Comoli P; Danziger-Isakov L; Dipchand AI; Esquivel CO; Ferry JA; Gross TG; Hayashi RJ; Höcker B; L'Huillier AG; Marks SD; Mazariegos GV; Squires J; Swerdlow SH; Trappe RU; Visner G; Webber SA; Wilkinson JD; Maecker-Kolhoff B
Pediatr Transplant; 2024 Feb; 28(1):e14471. PubMed ID: 37294621
[TBL] [Abstract][Full Text] [Related]
32. Transplantation of solid organ recipients shedding Epstein-Barr virus DNA pre-transplant: A prospective study.
Verghese PS; Schmeling DO; Filtz EA; Grimm JM; Matas AJ; Balfour HH
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28915342
[TBL] [Abstract][Full Text] [Related]
33. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease.
Campe H; Jaeger G; Abou-Ajram C; Nitschko H; Griebel M; Montoya C; Klare B; Koszinowski U
Pediatr Transplant; 2003 Feb; 7(1):46-52. PubMed ID: 12581328
[TBL] [Abstract][Full Text] [Related]
34. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
35. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
36. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
37. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.
Kroll J; Li S; Levi M; Weinberg A
J Clin Virol; 2011 Nov; 52(3):231-5. PubMed ID: 21900040
[TBL] [Abstract][Full Text] [Related]
38. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
39. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.
Jabs WJ; Hennig H; Kittel M; Pethig K; Smets F; Bucsky P; Kirchner H; Wagner HJ
J Clin Microbiol; 2001 Feb; 39(2):564-9. PubMed ID: 11158107
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
Chang YC; Young RR; Mavis AM; Chambers ET; Kirmani S; Kelly MS; Kalu IC; Smith MJ; Lugo DJ
PLoS One; 2022; 17(10):e0269766. PubMed ID: 36256635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]